J&J Medical Connect
TALVEY®

(talquetamab-tgvs)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TALVEY - Use in Patients with Renal Impairment

Last Updated: 10/20/2026

SUMMARY  

  • No formal studies of TALVEY in patients with renal impairment have been conducted.1
  • Results of population pharmacokinetic analyses indicate that mild (60 mL/min/1.73m2 ≤ estimated glomerular filtration rate [eGFR] <90 mL/min/1.73m2) or moderate renal impairment (30 mL/min/1.73m2 ≤ eGFR <60 mL/min/1.73m2) did not significantly influence the pharmacokinetics of TALVEY. Limited data (n=3) are available in patients with severe renal impairment.1
  • Based on population pharmacokinetic analyses, no dose adjustment is recommended for patients with mild or moderate renal impairment.1
  • MonumenTAL-1 is an ongoing, open-label, phase 1/2 study evaluating the efficacy and safety of TALVEY in patients with relapsed or refractory multiple myeloma (RRMM) after ≥3 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug, and an anti-CD38 monoclonal antibody.2-4 
    • Per protocol, patients enrolled in the study were required to have adequate renal function during the screening phase described as: creatinine clearance ≥40 mL/min/1.73m2 based upon Modified Diet in Renal Disease (MDRD) formula calculation.4,5 
    • Krishnan et al (2023)6 presented subgroup analyses of the efficacy and safety results from the MonumenTAL-1 study phases 1/2 in patients who received TALVEY at the recommended phase 2 doses (RP2D) of 0.4 mg/kg subcutaneous (SC) weekly (QW) and 0.8 mg/kg SC once every other week (Q2W), including those who were naïve or exposed to T-cell redirection (TCR) therapy. Data was presented from key high-risk subgroups, including patients with renal impairment (baseline function ≤60 mL/min/1.73 m2).
  • Ali et al (2026)7 published results from a retrospective, single-center cohort study of TALVEY in patients with RRMM including those with renal impairment (n=12) and without renal impairment (n=24) at a median follow-up of 7.3 months in the overall cohort.
  • Joiner et al (2025)8 presented results from a multicenter, retrospective cohort study of patients with RRMM treated with TALVEY including those with renal impairment (n=91) and without renal impairment (n=326) at a median follow-up of 11.1 months.
  • In addition to the data summarized above, a case series has been identified.9 

CLINICAL DATA – MONUMENTAL-1 STUDY

Krishnan et al (2023)6 evaluated the efficacy and safety of TALVEY in key high-risk subgroups of patients from phases 1/2 of the MonumenTAL-1 study.

Results

Treatment Disposition, Patient Demographics, and Disease/Treatment Characteristics

  • The subgroup analysis included 143 patients in the 0.4 mg/kg SC QW cohort and 145 patients in the 0.8 mg/kg SC Q2W cohort.
  • A total of 40 patients (28%) in the 0.4 mg/kg SC QW cohort and 45 patients (31%) in the 0.8 mg/kg SC Q2W cohort with renal impairment (baseline function ≤60 mL/min/1.73 m2) were included in the analysis.
  • Baseline demographic characteristics overall and in patients with renal impairment are presented in the Table: MonumenTAL-1: Baseline Demographic Characteristics in Patients with Renal Impairment.

MonumenTAL-1: Baseline Demographic Characteristics in Patients with Renal Impairment6
Parameter
TALVEY
0.4 mg/kg SC QW Dose
TALVEY
0.8 mg/kg SC Q2W Dose
Overall (N=143)
Renal Impairment (n=40)
Overall (N=145)
Renal Impairment (n=45)
Median age, years
67.0
69.0
67.0
68.0
Male, n (%)
78 (54.5)
19 (47.5)
83 (57.2)
23 (51.1)
Race, n (%)
   White
128 (89.5)
37 (92.5)
125 (86.2)
41 (91.1)
   Black/African American
   Asian
12 (8.4)
1 (0.7)
2 (5.0)
0
9 (6.2)
6 (4.1)
3 (6.7)
0
   Native Hawaiian/OPI
0
0
1 (0.7)
1 (2.2)
   Not reported/unknown
2 (1.4)
1 (2.5)
3 (2.1)
0
Ethnicitya, n (%)
   Non-Hispanic/Latino
132 (92.3)
38 (95.0)
127 (87.6)
41 (91.1)
   Hispanic or Latino
11 (7.7)
2 (5.0)
17 (11.7)
4 (8.9)
ECOG PS, n (%)
   0
44 (30.8)
7 (17.5)
56 (38.6)
13 (28.9)
   1
86 (60.1)
28 (70.0)
81 (55.9)
31 (68.9)
   2
13 (9.1)
5 (12.5)
8 (5.5)
1 (2.2)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; OPI, other Pacific Islander; Q2W, every other week; QW, weekly; SC, subcutaneous.aEthnicity was not reported for 1 patient in the overall Q2W population (N=145).Note: Data cut-off date is January 17, 2023.

Efficacy


MonumenTAL-1: ORR in Patients with Renal Impairment6
Parameter
TALVEY
0.4 mg/kg SC QW Dose
TALVEY
0.8 mg/kg SC Q2W Dose
Overall (N=143)
Renal Impairment (n=40)
Overall (N=145)
Renal Impairment (n=45)
Median follow-up, months
18.8
19.5
12.7
13.0
ORR, n (%)
106 (74.1)
26 (65.0)
104 (71.7)
30 (66.7)
Abbreviations: ORR, overall response rate; Q2W, every other week; QW, once weekly; SC, subcutaneous.Note: Data cut-off date is January 17, 2023.

Safety


MonumenTAL-1: Summary of AEs in Patients with Renal Impairment6
Parameter, n (%)
TALVEY
0.4 mg/kg SC QW Dose
TALVEY
0.8 mg/kg SC Q2W Dose
Overall (N=143)
Renal Impairment (n=40)
Overall (N=145)
Renal Impairment (n=45)
Any grade
143 (100.0)
40 (100.0)
145 (100.0)
45 (100.0)
Grade 3/4
111 (77.6)
30 (75.0)
113 (77.9)
34 (75.6)
Discontinuations
7 (4.9)
2 (5.0)
12 (8.3)
6 (13.3)
CRS
113 (79.0)
29 (72.5)
108 (74.5)
33 (73.3)
Dysgeusiaa
103 (72.0)
27 (67.5)
103 (71.0)
30 (66.7)
Infections
84 (58.7)
27 (67.5)
96 (66.2)
30 (66.7)
Skin relatedb
80 (55.9)
18 (45.0)
106 (73.1)
33 (73.3)
Nail relatedc
78 (54.5)
26 (65.0)
78 (53.8)
16 (35.6)
Rash relatedd
57 (39.9)
12 (30.0)
43 (29.7)
16 (35.6)
Abbreviations: AE, adverse event; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events; Q2W, every other week; QW, weekly; SC, subcutaneous.aIncludes ageusia, dysgeusia, hypogeusia, and taste disorder. Per CTCAE, the maximum possible grade of dysgeusia is 2. bIncludes skin exfoliation, dry skin, pruritus, and palmar-plantar erythrodysesthesia syndrome. cIncludes nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, nail dystrophy, nail toxicity, and nail ridging. dIncludes rash, maculopapular rash, erythematous rash, and erythema.Note: Data cut-off date is January 17, 2023.

retrospective Studies

Ali et al (2026)7 published results from a retrospective, single-center cohort study evaluating the efficacy and safety of TALVEY in patients with RRMM (with and without renal impairment) at a median follow-up of 7.3 months in the overall population.

Study Design/Methods

  • The study period started on March 30, 2023, with a data cutoff date of June 25, 2025.
  • Patients with RRMM who received ≥1 dose of TALVEY were included in the study.
  • TALVEY was administered subcutaneously using an inpatient sequential escalating step-up dosing schedule (0.01 mg/kg, 0.06 mg/kg, 0.4 mg/kg, and 0.8 mg/kg), followed by a biweekly maintenance dose of 0.8 mg/kg.
  • Patients were stratified into a renal impairment cohort (creatinine clearance [CrCl] <40 mL/min) and a no-renal impairment cohort (CrCl ≥40 mL/min). Additional predefined subgroups included severe renal impairment (CrCl <30 mL/min) and dialysis-dependent patients.

Results

Treatment Disposition, Patient Demographics, and Disease/Treatment Characteristics

  • A total of 36 patients who initiated TALVEY were included in the study.
  • The renal impairment cohort included 12 patients (33.3%), and the no-renal impairment cohort included 24 patients (66.7%). The severe renal impairment subgroup included 7 patients (19.4%), and the dialysis-dependent subgroup included 5 patients (13.9%).
  • The median follow-up was 7.3 months (95% CI, 4.5-10.5) in the overall population.
  • Baseline patient characteristics are summarized in Table: Select Baseline Patient Characteristics at TALVEY Initiation.

Select Baseline Patient Characteristics at TALVEY Initiation7
Characteristic
No Renal Impairment (n=24)
Renal Impairment
(n=12)

Median age, years (IQR)
68 (60-72.3)
66.5 (59.8-71)
Gender, n (%)
   Male
15 (62.5)
6 (50)
   Female
9 (37.5)
6 (50)
Cytogenetic risk, n (%)
   Standard-risk cytogenetics
10 (41.7)
1 (8.3)
   High-risk cytogenetics
5 (20.8)
8 (66.7)
   Double-hit MM
6 (25)
3 (25)
   Triple-hit MM
3 (12.5)
0
ECOG PS, n (%)
0
1 (4.1)
2 (16.7)
   1
10 (41.7)
5 (41.6)
   2
10 (41.7)
3 (25)
   3
3 (12.5)
2 (16.7)
Extramedullary disease, n (%)
4 (16.7)
2 (16.7)
Treatment refractoriness
   Number of prior lines of therapy, median (IQR)
7.5 (5-9)
6 (5-8)
   Triple-class refractory, n (%)
23 (95.8)
12 (100)
   Penta-class refractory, n (%)
18 (75)
11 (91.7)
   Previous ASCT, n (%)
14 (58.3)
7 (58.3)
   Previous BCMA-directed therapy, n (%)
21 (87.5)
10 (83.3)
Abbreviations: ASCT, autologous stem cell transplantation; BCMA, B-cell maturation antigen; CrCl, creatinine clearance; IQR, interquartile range; MM, multiple myeloma; RI, renal impairment.

Efficacy

  • Response at day 30, day 90, and best overall response outcomes are summarized in Table: Response Outcomes by Renal Impairment Status.
  • Survival outcomes are summarized in Table: Survival Outcomes by Renal Impairment Status.
  • Progression-free survival (PFS) was 7.49 months (95% CI, 1.64–NR) in the severe RI subgroup compared to 3.65 months (95% CI, 2.10–7.88) in the no severe RI subgroup.
  • No significant differences in OS were observed between patients with severe renal impairment and those without severe renal impairment.
  • No significant differences in OS or PFS were observed between dialysis dependent and non-dialysis-dependent patients.

Response Outcomes by Renal Impairment Status7
Outcome, n (%)
No Renal Impairmenta (n=24)
Renal Impairmentb (n=12)
Severe Renal Impairmentc (n=7)
Dialysis-Dependentd
(n=5)

Day 30
   ORR
11 (45.8)
6 (50.0)
-
-
      VGPR
2 (8.3)
4 (33.3)
3 (42.9)
3 (60.0)
      PR
8 (33.3)
0
-
-
   ≥CR
1 (4.2)
2 (16.7)
-
-
   SD
8 (33.3)
4 (33.3)
-
-
   PD
5 (20.8)
2 (16.7)
-
-
Day 90
   ORR
6 (25.0)
8 (66.7)
4 (57.1)
4 (80.0)
      VGPR
1 (4.2)
2 (16.7)
-
-
      PR
3 (12.5)
NR
-
-
   ≥CR
2 (8.3)
4 (33.3)
NR
1 (20.0)
   PD
9 (37.5)
NR
0
0
   Non-evaluable
   response

7 (29.2)
NR
-
-
Best overall response
   ORR
54.1
66.6
57.2
80
      PR
37.5
8.3
14.3
20
   ≥CR
8.3
33.3
14.3
20
   ≥VGPR
8.3
25
28.6
40
Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response; NR, not reported.Note: Median follow-up: 7.3 months (95% CI, 4.5-10.5) in the overall population.aMedian follow-up: 6.4 months (95% CI, 3.2-9.3)bMedian follow-up: 11.4 months (95% CI, 4.7-18.2)cMedian follow-up: 4.7 months (95% CI, 3.7-10.4)dMedian follow-up: 7.5 months (95% CI, 3.7-15.1)

Survival Outcomes by Renal Impairment Status7
Cohort
Median PFS,
months (95% CI)

P Value for PFS
Median OS,
Months (95% CI)

P Value for OS
Renal impairmenta
   No
2.63 (2.07-5.26)
0.006
8.71 (3.25-NR)
0.092
   Yes
8.48 (7.49-NR)
NR (10.38-NR)
Severe renal impairmentb
   No
3.65 (2.10-7.88)
0.22
10.58 (5.85-NR)
0.72
   Yes
7.49 (1.64-NR)
7.49 (3.68-NR)
Dialysis-dependentc
   No
3.65 (2.10-7.88)
0.17
10.58 (5.85-NR)
0.98
   Yes
9.56 (7.49-NR)
10.38 (7.49-NR)
Abbreviations: CI, confidence interval; NR, not reached; OS, overall survival; PFS, progression-free survival.Note: Median follow-up: 7.3 months (95% CI, 4.5-10.5) in the overall population.aMedian follow-up: 11.4 months (95% CI, 4.7-18.2)bMedian follow-up: 4.7 months (95% CI, 3.7-10.4)cMedian follow-up: 7.5 months (95% CI, 3.7-15.1)

Safety

  • Safety outcomes are summarized in Table: Safety Summary.
  • CRS episodes had a median duration of 1 day in both cohorts, while ICANS episodes had a median duration of 2 days in both cohorts.
  • Hospital utilization outcomes are summarized in Table: Hospital Utilization Outcomes.

Safety Summary7
Outcome, %
No Renal Impairmenta (n=24)
Renal Impairmentb (n=12)
OR (95% CI)
CRS
   Any-grade
66.7
66.7
-
   Grade 1
45.8
58.3
1.66 (0.43-6.32)
   Grade ≥3
8.3
8.3
-
   Recurrent
16.7
8.3
0.45 (0.05-4.59)
   Treatment used
      Tocilizumab
66.7
66.7
-
      Corticosteroids
20.8
16.7
-
      Anakinra
4.2
8.3
-
ICANS
   Any-grade
20.8
16.7
0.76 (0.12-4.64)
   Grade ≥3
12.5
8.3
0.64 (0.06-6.86)
   Treatment used
      Tocilizumab
20.8
8.3
-
      Corticosteroids
16.7
16.7
-
      Anakinra
4.2
0
-
Infections
   Bacterial
16.7
8.3
-
   Viral
8.3
8.3
-
   Fungal
4.2
0
-
Dysgeusia
83.3
83.3
-
Skin-related events
58.3
75
2.14 (0.46-9.98)
Nail-related events
54.2
83.3
4.23 (0.76-23.57)
Abbreviations: CI, confidence interval; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; OR, odds ratio.Note: Median follow-up: 7.3 months (95% CI, 4.5-10.5) in the overall population.aMedian follow-up: 6.4 months (95% CI, 3.2-9.3)bMedian follow-up: 11.4 months (95% CI, 4.7-18.2)

Hospital Utilization Outcomes7
Outcome
No Renal Impairmenta
(n=24)
Renal Impairmentb
(n=12)
Median inpatient length of stay during step-up dosing, days (range)
9 (8-24)
10 (7-25)
ICU admission during first cycle, %
4.2
0
Abbreviation: ICU, intensive care unit.Note: Median follow-up: 7.3 months (95% CI, 4.5-10.5) in the overall population.aMedian follow-up: 6.4 months (95% CI, 3.2-9.3)bMedian follow-up: 11.4 months (95% CI, 4.7-18.2)

Joiner et al (2025)8 presented results from a multicenter, retrospective cohort study evaluating TALVEY in patients with RRMM (with and without renal impairment) at a median follow-up of 11.1 months.

Results

Treatment Disposition, Patient Demographics, and Disease/Treatment Characteristics

  • A total of 417 patients who received TALVEY and had complete datasets were included in this study. See Table: Select Baseline Characteristics.
  • Renal impairment was defined as CrCl <40 mL/min. Among the patients with renal impairment, 5% (n=20) received dialysis.
  • No differences in performance status, race, presence of high-risk cytogenetic abnormalities [del17p, t(4;14), t(14;16), gain/amplification 1q] were reported.

Select Baseline Characteristics8
Characteristic
Without RI
(n=326)

With RI
(n=91)

Median age, years
65
68
Female, %
51
64
Prior CAR-T cell therapy, %
48
35
Median prior lines of therapy
6
6
Prior ASCT, %
72
68
CNS disease, %
4
4
Prior plasma cell leukemia, %
9
8
Prior BCMA-directed therapy, %
61
54
Triple-class refractory disease, %
94
90
Abbreviations: ASCT, autologous stem cell transplantation; BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor T-cell therapy; CNS, central nervous system.

Efficacy


Efficacy Outcomes in Patients With and Without Renal Impairment8
Endpoint
Without Renal impairment
(n=326)
With Renal impairment
(n=91)
P value
ORR, %
67
60
0.12
Median PFSa, months
6.5
7.3
0.9
BCMA-directed therapy naïve
   Median PFS,a
6.2
8.5
-
   Median OS, months
NR
NR
-
   12-month OS rate, %
73
71
0.53
Prior BCMA-directed therapy
   Median PFS,a
6.5
4.6
-
   Median OS, months
13.8
8.9
-
   12-month OS rate, %
59
43
0.06
Abbreviations: BCMA, B-cell maturation antigen; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.aPatients who received TALVEY as bridging therapy prior to CAR-T cell therapy were censored for PFS analysis at the time of subsequent therapy.

Safety

  • CRS and ICANS outcomes are summarized in Table: CRS and ICANS in Patients With and Without Renal Impairment.
  • No difference in infection risk was observed between patients with and without renal impairment (P=0.65). The cumulative risk of infection at 6 months was 39% in patients with renal impairment and 40% in patients without renal impairment.

CRS and ICANS in Patients With and Without Renal Impairment8
AE, %
No Renal Impairment (n=326)
Renal Impairment (n=91)
P Value
CRS
   Any-grade
56
63
0.21
   Grade ≥3
2
6
0.02
ICANS
   Any-grade
14
20
0.21
   Grade ≥3
4
4
0.97
Abbreviations: CRS, cytokine release syndrome; ICANS, immune cell-associated neurotoxicity syndrome.

literature search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 19 October 2026.

 

References

1 Data on File. Talquetamab. CCDS. Janssen Research & Development, LLC. EDMS-RIM-620984; version 007; 2026.  
2 Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12(4):e269-e281.  
3 Rasche L, Schinke C, Touzeau C, et al. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. [published online ahead of print on August 10, 2026]. Blood. doi:10.1182/blood.2025031994.  
4 Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244.  
5 Chari A, Minnema MC, Berdeja JG. Protocol to: Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244.  
6 Krishnan A, Costa L, Schinke C, et al. Talquetamab, a GPRC5D×CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from MonumenTAL-1. Poster presented at: The 20th International Myeloma Society (IMS) Annual Meeting and Exposition; September 27-30, 2023; Athens, Greece.  
7 Ali HM, Mazzoni S, Goel U, et al. Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort. Blood Cancer Journal. 2026;16:65.  
8 Joiner L, Pasvolsky O, Afrough A, et al. Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI). Blood. 2025;146(Supplement 1):827-827.  
9 Tokarski R, Catanzaro J, R M, et al. Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series. Clinical Lymphoma Myeloma and Leukemia. 2025;25:S58.  

Would you like to clear and leave your conversation? Message history will be lost.